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Background/aim: Attention deficit and hyperactivity disorder (ADHD) is a widespread neurodevelopmental disorder that begins in
childhood and has negative consequences throughout adult life. The etiology and pathogenesis of ADHD are still unclear. Tau protein
is a soluble microtubule-related protein expressed by neurons and localized in the cytoplasm as well as axons. Tau protein provides
stability of microtubule in two ways: phosphorylation and isoforms. The excessive phosphorylation of Tau separates the protein from the
microtubule, thus making it unstable. In this study, we aimed to investigate whether there is a relationship between serum Tau protein
and phospho Tau (p-Tau181) levels and ADHD occurrence.
Materials and methods: This study included 26 male children aged 7–12 years with newly diagnosed ADHD, who had previously not
used any medication for ADHD, and 26 male healthy children. Serum Tau and p-Tau181 concentrations were performed by enzymelinked immunosorbent assay (ELISA).
Results: In patients, the Tau levels were not significantly different from those of the controls; the p-Tau181 levels were significantly
higher than those of the controls.
Conclusion: We concluded that high p-Tau181 might be associated with the progression of ADHD and cognitive changes in ADHD.
Key words: Attention deficit and hyperactivity disorder, Tau, phospho Tau

1. Introduction
Attention deficit and hyperactivity disorder (ADHD) is one
of the common neuropsychiatric disorders of childhood.
It is a lifelong disorder that causes significant loss of
functionality in many areas. It negatively affects the quality
of life of the patient and family, and therefore the society
[1,2]. ADHD is defined as the inability to sustain attention
and/or symptoms of hyperactivity and impulsivity that
are more severe, continuous, or frequent compared to
individuals of similar age and developmental levels [3].
Neuropsychiatric disorders, such as ADHD, are quite
common in the population. Although they may stand to
express modifications in brain duty, they are not defined
by clear neuropathology and the underlying biochemical
conditions are mainly unrecognized. In other words,
the etiology and pathogenesis of ADHD are still unclear
[4]. Therefore, new research to explore ADHD is presently
ongoing.
Tau is a soluble microtubule-associated protein required
for polymerization and stabilization of the microtubular

cytoskeleton [5]. It is placed in the brain and spinal
cord, primarily in axons. Tau protein undergoes many
posttranslational modifications, and the most important
is phosphorylation, which regulates both normal and
pathological functions of Tau. Over phosphorylation
reduces Tau (p-Tau) affinity for microtubules, damaging
normal functions and decreasing biological activity
[6]. p-Tau separates from the microtubule and thus
destabilizes it [7]. The neuron loses viability as a result of
the cytoskeleton and cellular transport disruption. Tau is
released into the cerebrospinal fluid (CSF) and plasma by
disrupting cell integrity. Therefore, CSF and plasma Tau/
pTau levels can be used as a marker in the diagnosis of
some diseases and in determining the severity of axonal
damage [8].
There are few studies on psychiatric disorders related
to Tau and pTau pathology. In a study, serum total Tau
and pTau levels were found to be low in schizophrenia
[9]. Studies in rats showed that chronic stress triggers Tau
hyperphosphorylation [10]. In another study, autopsy
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samples were examined and Tau was shown to be higher
in suicide cases [11]. Total Tau levels were found to be
significantly lower in children with autism spectrum
disorder compared to the control [12]. These findings
suggest that Tau and pTau may also play a role in the
pathogenesis of psychiatric disorders. Information on
serum Tau and phospho Tau (p-Tau181) protein levels in
ADHD and its role in the pathogenesis of the disorder is
very weak. There is a study in the literature on ADHD, and
only serum Tau levels were evaluated, not pTau, and they
were found to be high in the patient group [13]. Differently,
in the present study, we aimed to evaluate both serum total
Tau and p-Tau181 levels in ADHD.
2. Materials and methods
2.1. Type of population
This study was performed in the Biochemistry and
Child and Adolescent Psychiatry departments of Erciyes
University Medical Faculty. Twenty-six male children
aged 7–12 years, with newly diagnosed ADHD, who
had formerly not taken any medication for ADHD were
included. They were examined at the Child and Adolescent
Psychiatry Department, between August 2017 and July
2018. ADHD was diagnosed by two child and adolescent
psychiatrists based on the DSM V-TR diagnostic criteria
and the short form of the Conners’ Parent Rating Scale.
Twenty-six healthy male children aged 7–12 years who
applied to the healthy children polyclinic in the Department
of Pediatrics were selected for the control group. These
children were included in the study after confirming that
they did not have any acute or chronic diseases (according
to their medical records) and that they did not have any
psychiatric disorders (a detailed psychiatric examination
was performed by two child and adolescent psychiatrists).
Written consent was obtained from the parents of children
to participate in the study.
2.2. Search strategy
Laboratory measurements were performed in the
Department of Biochemistry. After an overnight (12
h) fast, blood samples were collected from control and
patient groups into tubes without anticoagulants using the
venipuncture technique. The samples were enabled to clot
for 30 min and then centrifuged at 2000 rpm for 10 min
as usual. Hemolyzed and lipemic serums were excluded.
The aliquoted serum samples were stored at –80 °C for the
measurement of Tau and p-Tau181 concentrations.
Serum Tau protein and p-Tau181 concentrations were
measured by enzyme-linked immunosorbent assay (ELISA)
kits, Sunred and Elabscience, respectively. These kits were
based on biotin double antibody sandwich technology to
determine human Tau and phospho Tau levels in serum,
plasma, CSF, urine, and other body fluids; measurements
were performed as per the manufacturer’s instructions.

2108

The absorbance of each well was measured under 450 nm
wavelength. According to the standard concentrations and
their corresponding absorbances, we determined the Tau
protein and phospho Tau concentrations by calculating
the standard curve nonlinear regression equation.
2.3. Statistical analysis
Statistical analysis was performed using the TURCOSA
(Turcosa Analitik Ltd Co, Turkey) software. The normality
of the data was evaluated using the Shapiro–Wilk
normality test and Q–Q graphs. Data were expressed
as the number for categorical variables and mean ±
SD or median (25th–75th percentile) for continuous
variables. Age comparison between the two groups was
performed using the Independent Samples t-test. In terms
of Tau and phospho Tau, comparisons between groups
were performed with the Mann–Whitney U test. The
relationship between Tau and p-Tau was evaluated with
the Spearman correlation analysis. A p-value less than 0.05
was considered statistically significant.
2.4. Ethical statement
The ethical and methodological aspects of this investigation
were approved by the Institutional Review Board of Erciyes
University Medical Faculty. Written informed consent was
provided by the participants to join this study. We confirm
that all the methods were performed in compliance with
the relevant guidelines and regulations (Project No: TTU2017-7506).
3. Results
Our study involved 26 male children with ADHD and 26
male controls. The mean age of the controls was 9.08 ±
1.92 and the mean age of the children with ADHD was
8.85 ± 1.89 (p = 0.664).
Total Tau and p-Tau181 levels were not normally
distributed. Total Tau levels of ADHD were not
significantly different between groups (p = 0.092). p-Tau181
levels in children with ADHD were found to be statistically
significantly higher than those in controls (p = 0.046)
(Table, Figure).
In the control group, Tau levels were significantly
negatively correlated with p-Tau181 levels (r = –0.435 p =
0.026), while this correlation was not found in the ADHD
group (p = 0.584).
4. Discussion
Previous studies have suggested that CSF and plasma Tau/
p-Tau181 levels can be used as a marker in the diagnosis of
some diseases and in determining the severity of axonal
damage [6–8]. Although plasma/CSF levels have been
evaluated in many neurological diseases, there are limited
studies in psychiatric disorders.
As we mentioned above, there is a study on ADHD
in the literature. In this study, only serum total Tau levels
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Table. Total Tau and p-Tau181 protein levels in patient and control groups.
Groups

p-value

Patient (n = 26)

Control (n = 26)

Total Tau (ng/L)

21.3 (12.4–31.2)

25.4 (23.3–29.5)

0.092

p-Tau181 (pg/mL)

1859.6 (1646.6–2051.5)

1625.7 (1386.6–1896.7)

0.046
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Figure. Box plot graphics of p-Tau181 (left) and total Tau (right) in patient and control groups.

were evaluated, not pTau, and were found to be high in the
patient group. This finding was interpreted as that ADHD
may share a common mechanism with other diseases in
terms of tau pathology and may indicate a disturbance in
microtubule transport in the brain in this disorder [13].
In this study, we found no statistically significant
difference in Tau levels between the patient and control
groups. However, the numerical differences in Tau levels
(lower in ADHD) suggest that there may be a relationship
between Tau and ADHD by an as yet unknown mechanism.
A protein produced in the central nervous system can also
be detected in serum, but its concentration is approximately
10-fold lower compared to that in CSF. One explanation for
this condition is that it leaks into the circulation due to the
protein gradient through the impaired blood-brain barrier
(BBB) [14]. The low serum Tau levels in our study may
be due to the small amount of penetration of this protein
through the BBB into the serum. On the other hand, Tau
levels may be positively correlated with the number of
intact neurons. Tau concentration may vary depending on
the dynamic balance between CSF and serum leakage and
clearance. Therefore, less disabled patients with a larger
number of intact neurons secrete more Tau than patients
with pronounced brain atrophy. The numerical higher Tau
levels in the control group may be due to this reason.

To validate these numerical results, these preliminary
findings should be confirmed in an independent and large
group of ADHD.
We found that serum p-Tau181 levels were significantly
higher in the patient group compared to the controls.
While there was no correlation between Tau and p-Tau181
levels in the patient group, we found a negative correlation
in the control group.
It is known that p-Tau181 protein reflects neuronal
damage and leaks into CSF and serum after axonal damage
[14]. The increase in p-Tau181 concentration in ADHD
can be explained by axonal damage. It is possible for Tau
protein to undergo abnormally increased phosphorylation
in ADHD, as it has been detected in neurological diseases.
The results of our study appear to support that microtubule
pathology may play a role in ADHD pathogenesis.
However, the negative correlation between serum Tau
and p-Tau181 in the control group can be interpreted as that
the biochemistry of Tau may be more complex, and that
the level of Tau attempts to balance changes in p-Tau181
levels within certain limits.
As it was mentioned above, identifying protein markers
in blood has also a few benefits over CSF as it is easily
obtained from children patients in the clinic. Therefore,
the concept of blood-based biomarkers for ADHD is
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attractive and can be put into use in many areas, including
screening, diagnosis, risk assessment, and supporting
drug development in clinical trials. Until now, these
two proteins have been evaluated mainly as CSF-based
markers in clinical studies [15–19]. These results provide
valuable information that serum p-Tau181 is a promising
potential serum biomarker for the detection of ADHD
pathology. Validation of the data obtained with this smallscale study will be possible by supporting larger-scale and
well-controlled studies.
There are a few restrictions on this work. Firstly, the
patient number was low; therefore, there was not enough
statistical force in the investigation. Secondly, the subjects
consisted of only male children, female children were not
evaluated. Thirdly, kinetic serum Tau and p-Tau181 levels
were not explored. The uncovered ranges in the serum Tau
and p-Tau181 protein level could contain kinetic alterations
among different patients. Nonetheless, this work shows
the elementary proof that the serum p-Tau181 level could
operate as a supplementary marker to support the early
diagnosis of ADHD and the proper estimation of the
consequence of ADHD. Importantly, due to the lack of

equidistant studies in the literature, it is hard to measure
or note the similarities or dissimilarities of our study.
In conclusion, the serum p-Tau181 had a natural aptitude
or skill for separation between patients and controls from
ADHD. Therefore, serum p-Tau181 may serve as a predictive
protein marker for ADHD patients and may also be used
as a prognostic marker during follow-up of patients in the
future.
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